Exocrine Pancreatic Insufficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Exocrine Pancreatic Insufficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112024A7142
Buy Now

 Market Overview:

The 7 major exocrine pancreatic insufficiency markets reached a value of US$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.0 Billion by 2034, exhibiting a growth rate (CAGR) of 5.15% during 2024-2034.

Report Attribute
Key Statistics
Base Year  2023
Forecast Years  2024-2034
Historical Years 
2018-2023
Market Size in 2023
US$ 2.3 Billion
Market Forecast in 2034
US$ 4.0 Billion
Market Growth Rate 2024-2034
5.15%


The exocrine pancreatic insufficiency market has been comprehensively analyzed in IMARC's new report titled "Exocrine Pancreatic Insufficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Exocrine pancreatic insufficiency (EPI) refers to a condition in which the pancreas is unable to produce enough digestive enzymes to break down and absorb nutrients from food. This progressive loss of enzymes results in maldigestion, shortage of vitamins, and nutrient malabsorption from routine digestive processes. The symptoms of EPI are similar to many other gastrointestinal conditions and can range from mild to severe. Individuals suffering from this disease may experience abdominal discomfort, belly pain, bloating, diarrhea, fatigue, flatulence, bleeding disorders, edema, foul-smelling or fatty stool, unexplained weight loss, etc. The diagnosis of exocrine pancreatic insufficiency typically involves a review of the patient's symptoms, medical history, and diagnostic procedures. Various tests used to diagnose EPI include fecal elastase, which measures the level of pancreatic enzymes in the stool, and a secretin stimulation test, which assesses the ability of the pancreas to produce digestive enzymes. Several blood tests are also performed to check for nutrient deficiencies or other underlying disorders. In some cases, numerous imaging tests, such as an MRI or CT scan, are used to examine the condition of the pancreas.

Exocrine Pancreatic Insufficiency Market

The increasing incidence of chronic pancreatitis, which causes inflammation of the pancreas and impairs its ability to produce digestive enzymes, is primarily driving the exocrine pancreatic insufficiency market. Apart from this, the rising prevalence of inherited diseases, such as cystic fibrosis, that can block the pancreatic passageways and prevent the release of essential enzymes is also augmenting the market growth. Moreover, the widespread utilization of pancreatic enzyme replacement therapy for treating EPI, since it significantly enhances fat digestion and improves disease symptoms, is further creating a positive outlook for the market. Besides this, the inflating application of secretin-enhanced magnetic resonance cholangiopancreatography (MRCP), a noninvasive technique, to evaluate exocrine function and visualize changes in the pancreatic duct, is also propelling the market growth. Furthermore, numerous key players are making substantial investments in the development of new formulations of enzyme replacement therapy, including delayed-release enzymes designed to be released slowly over time and enzymes encapsulated in liposomes to improve absorption. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of combination treatments involving vitamin supplementation and lifestyle modification, such as cessation of smoking, limitation of alcohol intake, consumption of a healthy diet, etc., is expected to drive the exocrine pancreatic insufficiency market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the exocrine pancreatic insufficiency market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for exocrine pancreatic insufficiency and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the exocrine pancreatic insufficiency market in any manner.

Recent Developments:

  • In December 2023, Codexis, Inc. announced that it had signed a purchase agreement with Nestle Health Science for CDX-7108, which is an experimental medication for the treatment of exocrine pancreatic insufficiency.
  • In September 2023, Anagram Therapeutics Inc. reported that the first participants had been dosed in a randomized, multicenter, parallel research study to assess the tolerability and safety of orally administered ANG003 in adult individuals with CF-related exocrine pancreatic insufficiency. ANG003 is an innovative broad-spectrum enzyme replacement therapy used orally to treat malabsorption and exocrine pancreatic insufficiency.
  • In July 2023, First Wave BioPharma, Inc. disclosed that it had received topline results from its Phase 2 SPAN clinical trial, which is investigating an enhanced enteric micro granule delivery formulation of adrulipase for treating exocrine pancreatic insufficiency in cystic fibrosis (CF) patients. According to preliminary study results, the increased adrulipase formulation was safe and well tolerated, and it outperformed previous adrulipase formulations.


Key Highlights:

  • Exocrine pancreatic insufficiency affects around 60% to 90% of patients with chronic pancreatitis within 10 to 12 years after diagnosis.
  • Exocrine pancreatic insufficiency is the most frequent pancreas condition in the United States, with 42-73 cases per 100,000 persons.
  • The prevalence of exocrine pancreatic insufficiency in type 1 diabetes varies from 14% to 77.5% (median 33%), whereas in type 2 diabetes, it ranges between 16.8% to 49.2% (median 29%).
  • The prevalence of exocrine pancreatic insufficiency rises with age and appears to be higher in males than in women.
  • About 85 percent of cystic fibrosis patients have exocrine pancreatic insufficiency, necessitating pancreatic enzyme replacement treatment.


Drugs:                                               

Viokace is a compound made up of porcine-derived lipases, amylases, and proteases. In adults, Viokace combined with a proton pump inhibitor is approved for the treatment of exocrine pancreatic insufficiency caused by chronic pancreatitis or pancreatectomy. The drug contains the active component pancrelipase, which exists in the form of tablets that can be taken orally with each meal and snack.

CDX-7108 is a lipase variation designed to address the limits of current pancreatic enzyme replacement therapy (PERT) for treating exocrine pancreatic insufficiency. This therapeutic option is designed to be highly stable in acidic stomach conditions and resistant to proteases in the upper intestines.

MS1819 is a recombinant lipase produced from the yeast Yarrowia Lipolytica. It is under development to treat exocrine pancreatic insufficiency associated with chronic pancreatitis and CF. AzurRx is currently working on a Phase IIa trial of MS1819 to treat exocrine pancreatic insufficiency (EPI) caused by chronic pancreatic pancreatitis. The trial is being carried out at four sites in New Zealand and Australia, with a target enrollment of 12-15 participants.


Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the exocrine pancreatic insufficiency market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the exocrine pancreatic insufficiency market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs


Competitive Landscape:

This report also provides a detailed analysis of the current exocrine pancreatic insufficiency marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     
Drugs Company Name
Viokace (Pancrelipase immediate release) Nestle
Zenpep (Pancrelipase delayed release) Nestle
Pancreaze (Pancrelipase) Janssen Pharmaceuticals
Ultresa (Pancrelipase (Ultrase) delayed-release) AbbVie
Creon (Pancrelipase delayed-release capsules) AbbVie
CDX7108 Codexis
MS 1819 First Wave BioPharma/Mayoly-Spindler


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.


Key Questions Answered in this Report:

Market Insights

  • How has the exocrine pancreatic insufficiency market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the exocrine pancreatic insufficiency market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the exocrine pancreatic insufficiency market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of exocrine pancreatic insufficiency across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of exocrine pancreatic insufficiency by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of exocrine pancreatic insufficiency by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with exocrine pancreatic insufficiency across the seven major markets?
  • What is the size of the exocrine pancreatic insufficiency patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of exocrine pancreatic insufficiency?
  • What will be the growth rate of patients across the seven major markets?
     

Exocrine Pancreatic Insufficiency: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for exocrine pancreatic insufficiency drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the exocrine pancreatic insufficiency market?
  • What are the key regulatory events related to the exocrine pancreatic insufficiency market?
  • What is the structure of clinical trial landscape by status related to the exocrine pancreatic insufficiency market?
  • What is the structure of clinical trial landscape by phase related to the exocrine pancreatic insufficiency market?
  • What is the structure of clinical trial landscape by route of administration related to the exocrine pancreatic insufficiency market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Exocrine Pancreatic Insufficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARATI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More
DEinternational Egypt

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

Read More